Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets

Blood

Volumn 119, Issue 24, 2012, Pages 5795-5806

  Travert, Marion ^a,b,c   Huang, Yenlin ^a,b,d,e   De Leval, Laurence ^f   Martin Garcia, Nadine ^a,b,c   Delfau Larue, Marie Helene ^a,b,g   Berger, Françoise ^h   Bosq, Jacques ⁱ   Brière, Josette ^j   Soulier, Jean ^j   MacIntyre, Elizabeth ^k   Marafioti, Teresa ^b,l   De Reyniès, Aurélien ^m   Gaulard, Philippe ^a,b,c  

^a INSERM U955   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e CHANG GUNG UNIVERSITY   (Taiwan)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h CENTRE HOSPITALIER LYON SUD   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j SAINT LOUIS HOSPITAL   (France)

^k HÔPITAL NECKER ENFANTS MALADES   (France)

^l UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^m Cartes d'Identité des Tumeurs Program   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; PROTEIN KINASE SYK; SPHINGOSINE 1 PHOSPHATASE RECEPTOR 5; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL LINEAGE; CELL MIGRATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CPG ISLAND; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; ISOCHROMOSOME; MALE; NATURAL KILLER CELL; ONCOGENE; ONCOGENE C FOS; ONCOGENE VAV3; PRIORITY JOURNAL; T CELL LYMPHOMA; TUMOR SUPPRESSOR GENE;

EID: 84862492224     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-396150     Document Type: Article

References (50)

1. Gaulard P, Bourquelot P, Kanavaros P, et al. Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas. Am J Pathol. 1990;137(3):617-628. (Pubitemid 20280991)
2. Farcet JP, Gaulard P, Marolleau JP, et al. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood. 1990;75(11):2213-2219. (Pubitemid 20181173)
3. Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood. 1996;88(11):4265-4274. (Pubitemid 26399174)
4. Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 2003;102(13):4261-4269. (Pubitemid 37494082)
5. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44(2):265-267. (Pubitemid 46175082)
6. Macon WR, Williams ME, Greer JP, Cousar JB. Paracortical nodular T-cell lymphoma. Identification of an unusual variant of peripheral T-cell lymphoma. Am J Surg Pathol. 1995;19(3):297-303.
7. Suarez F, Wlodarska I, Rigal-Huguet F, et al. Hepatosplenic alphabeta T-cell lymphoma: an unusual case with clinical, histologic, and cytogenetic features of gammadelta hepatosplenic T-cell lymphoma. Am J Surg Pathol. 2000;24(7):1027-1032. (Pubitemid 30430492)
8. Swerdlow S, Campo E, Harris NL, eds. International Agency for Research on Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Geneva, Switzerland: World Health Organization; 2008.
9. Wlodarska I, Martin-Garcia N, Achten R, et al. Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes Chromosomes Cancer. 2002;33(3):243-251. (Pubitemid 34130930)
10. Bennett M, Matutes E, Gaulard P. Hepatosplenic T cell lymphoma responsive to 2 -deoxycoformycin therapy. Am J Hematol. 2010;85(9):727-729.
11. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952-4963.
12. Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest. 2007;117(3):823-834. (Pubitemid 46348541)
13. Iqbal J, Weisenburger DD, Chowdhury A, et al. Natural killer cell lymphoma shares strikingly similar molecular features with a group of nonhepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia. 2011;25(2):348-358.
14. Huang Y, de Reynies A, de Leval L, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood. 2010;115(6):1226-1237.
15. Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026-1036.
16. Ballester B, Ramuz O, Gisselbrecht C, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene. 2006;25(10):1560-1570. (Pubitemid 43361941)
17. Miyazaki K, Yamaguchi M, Imai H, et al. Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma. Blood. 2009;113(5):1071-1074.
18. Delfau-Larue MH, Dalac S, Lepage E, et al. Prognostic significance of a polymerase chain reac-tion-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides. Blood. 1998;92(9):3376-3380. (Pubitemid 28492347)
19. Kanavaros P, Farcet JP, Gaulard P, et al. Recombinative events of the T cell antigen receptor delta gene in peripheral T cell lymphomas. J Clin Invest. 1991;87(2):666-672.
20. Correia DV, d'Orey F, Cardoso BA, et al. Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells. PLoS One. 2009;4(5):e5657.
21. Zhang Y, Ohyashiki JH, Shimizu N, Ohyashiki K. Aberrant expression of NK cell receptors in Epstein-Barr virus-positive gammadelta T-cell lymphoproliferative disorders. Hematology. 2010;15(1):43-47.
22. Di Noto R, Pane F, Camera A, et al. Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/Tcry5+) and DERL-7 (CD56+/CD3-/TCRgammadelta-), derived from a single patient with CD56+ non-Hodgkin's lymphoma. Leukemia. 2001;15(10):1641-1649.
23. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717-721.
24. Caron G, Le Gallou S, Lamy T, Tarte K, Fest T. CXCR4 expression functionally discriminates centroblasts versus centrocytes within human germinal center B cells. J Immunol. 2009;182(12):7595-7602.
25. Travert M, Ame-Thomas P, Pangault C, et al. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NFkappaB activation and up-regulation of c-FLIP and Bcl-xL. J Immunol. 2008;181(2):1001-1011.
26. Capietto AH, Martinet L, Fournie JJ. Stimulated gammadelta T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer. J Immunol. 2011;187(2):1031-1038.
27. Jenne CN, Enders A, Rivera R, et al. T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. J Exp Med. 2009;206(11):2469-2481.
28. Ray ME, Su YA, Meltzer PS, Trent JM. Isolation and characterization of genes associated with chromosome-6 mediated tumor suppression in human malignant melanoma. Oncogene. 1996;12(12):2527-2533. (Pubitemid 26237781)
29. Zhao WL, Liu YY, Zhang QL, et al. PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. Blood. 2008;111(7):3867-3871.
30. Iqbal J, Kucuk C, Deleeuw RJ, et al. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia. 2009;23(6):1139-1151.
31. de Carvalho F, Colleoni GW, Almeida MS, Carvalho AL, Vettore AL. TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int J Cancer. 2009;125(8):1985-1991.
32. Feldman AL, Sun DX, Law ME, et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia. 2008;22(6):1139-1143. (Pubitemid 351833780)
33. Krenacs L, Smyth MJ, Bagdi E, et al. The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity. Blood. 2003;101(9):3590-3593. (Pubitemid 36857946)
34. Morice WG, Macon WR, Dogan A, Hanson CA, Kurtin PJ. NK-cell-associated receptor expression in hepatosplenic T-cell lymphoma, insights into pathogenesis. Leukemia. 2006;20(5):883-886.
35. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297-336. (Pubitemid 46697911)
36. Kelsen J, Dige A, Schwindt H, et al. Infliximab induces clonal expansion of gammadelta-T cells in Crohn's disease: a predictor of lymphoma risk? PLoS One. 2011;6(3):e17890.
37. Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007;316(5822):295-298. (Pubitemid 46633109)
38. Walzer T, Chiossone L, Chaix J, et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol. 2007;8(12):1337-1344. (Pubitemid 350131171)
39. Marie JP. Drug resistance in hematologic malignancies. Curr Opin Oncol. 2001;13(6):463-469.
40. Andreadis C, Gimotty PA, Wahl P, et al. Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood. 2007;109(8):3409-3416. (Pubitemid 46572530)
41. Wang B, Li XQ, Ma X, Hong X, Lu H, Guo Y. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol. 2008;83(10):795-799.
42. Michelutti A, Michieli M, Damiani D, et al. Effect of fludarabine and arabinosylcytosine on multidrug resistant cells. Haematologica. 1997;82(2):143-147. (Pubitemid 28023330)
43. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994;54(16):4313-4320. (Pubitemid 24273141)
44. Ribrag V, Koscielny S, Carpiuc I, et al. Prognostic value of GST-pi expression in diffuse large B-cell lymphomas. Leukemia. 2003;17(5):972-977. (Pubitemid 36626326)
45. Bennaceur-Griscelli A, Bosq J, Koscielny S, et al. High level of glutathione-S-transferase pi expression in mantle cell lymphomas. Clin Cancer Res. 2004;10(9):3029-3034. (Pubitemid 38619679)
46. Küçük C, Iqbal J, Hu X, et al. PRDM1 is a tumor suppressor gene in natural killer cell malignancies. Proc Natl Acad Sci U S A. 2011;108(50):20119-20124.
47. Pogue SL, Kurosaki T, Bolen J, Herbst R. B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase. J Immunol. 2000;165(3):1300-1306. (Pubitemid 30604558)
48. Gururajan M, Dasu T, Shahidain S, et al. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. J Immunol. 2007;178(1):111-121. (Pubitemid 46033592)
49. Wilcox RA, Sun DX, Novak A, Dogan A, Ansell SM, Feldman AL. Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines. Leukemia. 2010;24(1):229-232.
50. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578-2585.